Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharma (VRX) Outperforms Amid Broad Weakness
May 11, 2017 9:54 AM EDTValeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness
... MoreValeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
May 9, 2017 7:05 AM EDTValeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.
Adjusted EBITDA (non-GAAP) of $861 Million2017 Guidance
2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75... More
